Fundraising Fox

Sensorium Therapeutics

Medford, US · Founded 2021 · Delaware corporation · 7 known investors

sensorium.bio ↗

Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.

AI & Machine LearningBiotechDigital Healthin /sensorium-therapeutics

Founders & leadership

JR
Jerrold RosenbauminDirector
KL
Kevin LalandeinDirector
RS
Richard SimonDirector
BG
Balkrishan GillDirector
AG
Alexandra GlucksmannDirector
JH
Jacob HookerinExecutive Officer, Director
PT
Pranav TadiExecutive Officer
RK
Ryan KatzinDirector

Investors · 7

Bonaventure Equity, LLCRaleigh
Hatteras Venture PartnersResearch Triangle · $500K – $4M
Iter InvestmentsSouth Florida
Mission BiocapitalSan Francisco · $500K
Service Provider CapitalVail
Route 66 VenturesreportedAlexandria · $500K – $4M
Sante Health VenturesreportedAustin

Reported raises · per SEC filings

Form D private placements
▶$26.8MraisedJul 2025 · 19 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jerrold RosenbaumDirector
  • Ryan KatzDirector
  • Kevin LalandeDirector
  • Richard SimonDirector
  • Balkrishan GillDirector
  • Alexandra GlucksmannDirector
  • Jacob HookerExecutive Officer, Director
Offering amount
$58.5M
Amount sold
$26.8M
Proceeds to insiders
$531K
First sale
Jan 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$24.7MraisedDec 2023 · 64 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard SimonExecutive Officer, Director
  • Pranav TadiExecutive Officer
  • Jerrold RosenbaumDirector
  • Kevin LalandeDirector
  • Ryan KatzDirector
Offering amount
$24.8M
Amount sold
$24.7M
Proceeds to insiders
$750K
First sale
Sep 2022
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9MraisedJul 2021 · 47 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard SimonExecutive Officer, Director
  • Jerrold RosenbaumDirector
  • Pranav TadiExecutive Officer
Offering amount
$9M
Amount sold
$9M
Proceeds to insiders
$400K
First sale
Jul 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news